Insulin degludec
Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
| Series: | Journal of Mahatma Gandhi Institute of Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2013;volume=18;issue=2;spage=103;epage=108;aulast=Jain |
| _version_ | 1819240991048073216 |
|---|---|
| author | Vishakha V Jain Omprakash Gupta |
| author_facet | Vishakha V Jain Omprakash Gupta |
| author_sort | Vishakha V Jain |
| collection | DOAJ |
| description | Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus. Findings from clinical trials have demonstrated that new-generation, once-daily basal insulin degludec provides similar A1C control as compared to insulin glargine, both administered as basal-oral therapy or in combination with insulin aspart, with the added benefits of lower rates of hypoglycemia, particularly nocturnal hypoglycemia. |
| first_indexed | 2024-12-23T14:16:48Z |
| format | Article |
| id | doaj.art-1cc26f5eed4f484b868e6b5b9d00e11c |
| institution | Directory Open Access Journal |
| issn | 0971-9903 |
| language | English |
| last_indexed | 2024-12-23T14:16:48Z |
| publishDate | 2013-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Mahatma Gandhi Institute of Medical Sciences |
| spelling | doaj.art-1cc26f5eed4f484b868e6b5b9d00e11c2022-12-21T17:43:53ZengWolters Kluwer Medknow PublicationsJournal of Mahatma Gandhi Institute of Medical Sciences0971-99032013-01-0118210310810.4103/0971-9903.117795Insulin degludecVishakha V JainOmprakash GuptaInsulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus. Findings from clinical trials have demonstrated that new-generation, once-daily basal insulin degludec provides similar A1C control as compared to insulin glargine, both administered as basal-oral therapy or in combination with insulin aspart, with the added benefits of lower rates of hypoglycemia, particularly nocturnal hypoglycemia.http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2013;volume=18;issue=2;spage=103;epage=108;aulast=JainBasal insulininsulin analoguesinsulin degludec |
| spellingShingle | Vishakha V Jain Omprakash Gupta Insulin degludec Journal of Mahatma Gandhi Institute of Medical Sciences Basal insulin insulin analogues insulin degludec |
| title | Insulin degludec |
| title_full | Insulin degludec |
| title_fullStr | Insulin degludec |
| title_full_unstemmed | Insulin degludec |
| title_short | Insulin degludec |
| title_sort | insulin degludec |
| topic | Basal insulin insulin analogues insulin degludec |
| url | http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2013;volume=18;issue=2;spage=103;epage=108;aulast=Jain |
| work_keys_str_mv | AT vishakhavjain insulindegludec AT omprakashgupta insulindegludec |